German biotech MorphoSys said last week that it has signed an agreement with the University of Melbourne to jointly investigate new therapeutic applications for MOR103, MorphoSys' HuCAL antibody currently in development for treating rheumatoid arthritis.

Under the terms of the agreement, MorphoSys will fund research activities at the University of Melbourne in multiple new indications. The university will receive an undisclosed upfront payment and will be entitled to research funding and clinical milestone and royalty payments, MorphoSys said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.